Maze Therapeutics, Inc.
MAZE
Updated: 23/09/2026, 02:04:56
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
No summaries found.
- Share price
- $28.38
- Market cap
- $1.57B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jason Coloma
- Employees
- 141
- IPO date
- 31/01/2025
- Beta
- 2.16
- Last dividend
- $0.00
- Day range
- $24.50 – $29.40
- 52-week range
- $21.95 – $53.65
- 1-day performance
- 26.75%
- 1-year performance
- 29.29%
- Current drawdown (1Y)
- -47.10%
- CIK
- 0001842295
- CUSIP
- 578784100
- ISIN
- US5787841007
- Created
- 07/12/2025, 05:10:03
- Last update
- 23/09/2026, 02:04:56
Track Maze Therapeutics, Inc. with an AI analyst
See which prediction-market events move MAZE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Globe News Wire • STOCK • 27/05/2026, 09:03:06
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewsWire • STOCK • 27/05/2026, 09:03:00
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 12/05/2026, 20:16:10
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
GlobeNewsWire • STOCK • 12/05/2026, 18:01:00
Maze Therapeutics Announces $150 Million Registered Offering
GlobeNewsWire • STOCK • 22/04/2026, 02:09:00
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
The Motley Fool • STOCK • 04/04/2026, 21:36:00
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
Seeking Alpha • STOCK • 27/03/2026, 16:09:00
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
GlobeNewsWire • STOCK • 26/03/2026, 10:40:00
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
GlobeNewsWire • STOCK • 25/03/2026, 08:00:00
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
The Motley Fool • STOCK • 21/03/2026, 23:17:49
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
The Motley Fool • STOCK • 16/02/2026, 02:35:14
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
The Motley Fool • STOCK • 01/02/2026, 05:13:25